News and Announcements
OncoSil Appoints Michael Warrener as Global Sales and Marketing Director
- Published May 18, 2016 10:45AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
18th May 2016, ASX Announcement
OncoSil Medical Limited (ASX: OSL) (OncoSil Medical or the Company) is pleased to announce the appointment of Mr Michael Warrener as Global Sales and Marketing Director. Mr Warrener will be responsible for implementing the Company’s commercialisation strategy and infrastructure.
Mr Warrener will be based in Sydney and will oversee the initial market launch in Europe, Australia and key Asian markets. Mr Warrener will commence his role on 1st of June and his appointment completes the Senior Leadership Team of the Company.
Mr Warrener has forged a highly successful career in the pharmaceutical and medical device sector over a period of more than 23 years, including eight years with Sirtex Medical Ltd (ASX: SRX). During his time with Sirtex he held a number of senior management roles including Sales and Marketing Director for Europe and Middle East where he helped introduce then drive adoption of the Sir-Spheres product in the Australian, European Union and Middle East markets.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
